Alnylam Pharmaceuticals, Inc. (ETR:DUL)

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals had revenue of $1.25B USD in the quarter ending September 30, 2025, with 149.35% growth. This brings the company's revenue in the last twelve months to $3.21B, up 53.24% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.

• Revenue (ttm): $3.21B
• Revenue Growth: +53.24%
• P/S Ratio: 18.67
• Revenue / Employee: $1.44M
• Employees: 2,230
• Market Cap: 51.08B EUR

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	2.25B	419.95M	22.97%
Dec 31, 2023	1.83B	790.87M	76.23%
Dec 31, 2022	1.04B	193.13M	22.88%
Dec 31, 2021	844.29M	351.43M	71.31%
Dec 31, 2020	492.85M	273.10M	124.28%